Epirubicin plus docetaxel in metastatic breast cancer: Escalating dose does not improve efficacy. A phase II study

Anticancer Research

Volumn 24, Issue 3 B, 2004, Pages 1963-1967

  Fabi, Alessandra ^a   Papaldo, Paola ^a   Pino, Maria Simona ^a   Ferretti, Gianluigi ^a   Carlini, Paolo ^a   Pacetti, Umberto ^a   Di Cosimo, Serena ^a   Nardoni, Chiara ^a   Giannarelli, Diana ^a   Sacchi, Italo ^a   Cognetti, Francesco ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Docetaxel; Epirubicin; Epirubicin dose; Metastatic breast cancer

Indexed keywords

ANTHRACYCLINE ANTIBIOTIC AGENT; DEXAMETHASONE; DOCETAXEL; EPIRUBICIN; ESTROGEN RECEPTOR; METHYLPREDNISOLONE; PROGESTERONE RECEPTOR; RANITIDINE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TAXANE DERIVATIVE;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTHENIA; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BREAST CANCER; BREAST METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DOSE CALCULATION; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG ACTIVITY; DRUG DOSE REDUCTION; DRUG EFFICACY; FEBRILE NEUTROPENIA; FEMALE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; LEUKOPENIA; MUCOSA INFLAMMATION; MULTICENTER STUDY; MYALGIA; NAUSEA; NEUROLOGIC DISEASE; NEUTROPENIA; PARESTHESIA; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SKIN DISEASE; STOMATITIS; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DRUG ADMINISTRATION SCHEDULE; EPIRUBICIN; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; TAXOIDS;

EID: 3242686275     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Harris J R, Morrow M and Norton L: Malignant tumors of the breast. In: De Vita V T Jr, Hellman S, Rosenberg S A (eds), Cancer: Principles and Practice of Oncology. J B Lippincott: Philadelphia, 1557-1616, 1997.
2. Gebbia V, Blasi L, Borsellino et al: Paclitaxel and epidoxorubicin or doxorubicin versus cyclophosphamide and doxorubicin as first-line chemotherapy for metastatic breast carcinoma: a randomized phase II study. Anticancer Res 23: 765-771, 2003.
3. Zoli W, Flamigni A, Frassinetti GL et al: In vitro activity of taxol and taxotere in comparison with doxorubicin and cisplatin on primary cell cultures of human breast cancer. Breast Cancer Res 34: 63-69, 1995.
4. Fumoleau P: Treatment of patients with liver metastases. Anticancer Drugs 7: 21-33, 1996.
5. Italian Multicenter Breast Study with Epirubicin: Phase III randomized study of fluorouracil, epirubicin and cyclophosphamide vs fluorouracil, doxorubicin and cyclophosphamide in advanced breast cancer. J Clin Oncol 6: 976-982, 1988.
6. Ravdin P, Valero V, Burris H et al: Phase II trial of docetaxel in advanced anthracyclines-resistant or anthracenedione-resistant breast cancer. J Clin Oncol 13: 2879-2885, 1995.
7. Bonneterre J, Dieras V, Tubiana-Hulin M et al: 6 cycles of Epirubicin/Docetaxel (ET) versus 6 cycles of 5FU Epirubicin/Cyclophosphamide (FEC) as first line metastatic breast cancer (MBC) treatment. Proc Am Soc Clin Oncol 20: 42a, 2001.
8. Pagani O, Sessa C, Martinelli G et al: Dose-finding study of epirubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer. Ann Oncol 10: 539-545, 1999.
9. Venturini M, Michelotti A, Papaldo P et al: Identification of the highest dose of docetaxel associable with active doses of epirubicin. Results from a dose-finding study in advanced breast cancer patients. Ann Oncol 12: 1097-1106, 2001.
10. Miller A, Hoogstraten B, Staquet M et al: Reporting results of cancer treatment. Cancer 47: 207-214, 1981.
11. Kaplan EL and Meier P: Nonparametric estimation from incomplete observation. J Am Stat Assoc 53: 475-481, 1958.
12. Milla-Santos A, Milla L, Rallo L et al: High-dose epirubicin plus docetaxel at standard dose with lenograstim support as first-line therapy in advanced breast cancer. Am J Clin Oncol 24: 138-142, 2001.
13. Astone A, Fedele P, Cassano A et al: Two-day epirubicin (E) plus docetaxel (D) as first-line chemotherapy for stage IIIb-IV breast cancer (BC). Preliminary report. Proc Am Soc Clin Oncol 19: 454a, 2000.
14. Steger GG, Wenzel C, Schmidinger M et al: Phase II evaluation of docetaxel and epidoxorubicin + G-CSF (DE+G) in primary and advanced breast cancer. Breast Cancer Res Treat 57: 346a, 1999.
15. Eidtmann H, Astner A, Ernhardt B et al: Phase II study of docetaxel and epirubicin as first-line chemotherapy in metastatic breast cancer. Proc Am Soc Clin Oncol 19: 442a, 2000.
16. Pagani O, Sessa C, Nolè F et al: Epirubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer: a multicenter phase I-II study. Ann Oncol 11: 985-991, 2000.
17. Kourossis C, Xydakis E, Potamianou A et al: Front-line treatment of metastatic breast cancer with docetaxel and epirubicin: a multicenter dose-escalation study. Ann Oncol 10: 547-552, 1999.
18. Mavroudis D, Alexopoulos A, Ziras N et al: Front-line treatment of advanced breast cancer with docetaxel and epirubicin: a multicenter phase II study. Ann Oncol 11: 1249-1254, 2000.
19. Estevez LG, Domine M, Martin I et al: Docetaxel (T) in combination with epirubicin (E) as treatment of metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 19: 119A, 2000.
20. Dominguez S, Morales S, Castellanos J et al: Combination of two active drugs; epirubicin-docetaxel (ET) in advanced breast cancer (ABC): preliminary results. Proc Am Soc Clin Oncol 19: 110a, 2000.
21. Vienz P, Rochè H, Kerbrat P et al: Epirubicin-docetaxel combination in first-line chemotherapy for patients with metastatic breast cancer. Am J Clin Oncol 24: 328-335, 2001.
22. Polyzos A, Tsavaris N, Kosmas C et al: Docetaxel and epirubicin supported by granulocyte colony-stimulating factor first-line in advanced breast cancer. Anticancer Res 24: 2917-2923, 2003.
23. Trudeau ME, Crump M, Latreille K et al: Escalating doses o docetaxel and epirubicin as first line therapy for metastatic breast cancer. A phase I/II study of the National Cancer Institute of Canada-Clinical trials group. Proc Am Soc Clin Oncol 18: 117a, 1999.